Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
- Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 -- Aligos Therapeutics, Inc. , a clinical...